Axon Enterprise, Inc $AXON Shares Sold by Thematics Asset Management

Thematics Asset Management cut its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 5.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,568 shares of the biotechnology company’s stock after selling 1,524 shares during the period. Thematics Asset Management’s holdings in Axon Enterprise were worth $18,349,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. NEOS Investment Management LLC raised its stake in Axon Enterprise by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock valued at $18,206,000 after acquiring an additional 11,482 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Axon Enterprise by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Axon Enterprise by 3.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock worth $132,349,000 after purchasing an additional 5,953 shares during the period. BIT Capital GmbH grew its position in Axon Enterprise by 75.6% in the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock valued at $2,537,000 after buying an additional 1,522 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC increased its stake in Axon Enterprise by 180.7% in the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock valued at $997,000 after buying an additional 775 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Down 0.6%

AXON stock opened at $496.18 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.53 and a quick ratio of 2.29. The company’s 50 day simple moving average is $531.08 and its 200-day simple moving average is $610.44. The firm has a market capitalization of $39.89 billion, a PE ratio of 326.44, a P/E/G ratio of 10.66 and a beta of 1.46. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The company’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.08 earnings per share. Equities analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at $7,019,028. The trade was a 10.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Isaiah Fields sold 2,000 shares of the company’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $535.01, for a total value of $1,070,020.00. Following the completion of the transaction, the insider owned 55,588 shares of the company’s stock, valued at $29,740,135.88. The trade was a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 24,634 shares of company stock valued at $13,803,095. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on AXON shares. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. Wall Street Zen raised Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group dropped their target price on Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 25th. Needham & Company LLC cut their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Finally, Craig Hallum reissued a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.